JP2019534304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534304A5 JP2019534304A5 JP2019524273A JP2019524273A JP2019534304A5 JP 2019534304 A5 JP2019534304 A5 JP 2019534304A5 JP 2019524273 A JP2019524273 A JP 2019524273A JP 2019524273 A JP2019524273 A JP 2019524273A JP 2019534304 A5 JP2019534304 A5 JP 2019534304A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 162
- 150000003839 salts Chemical class 0.000 claims description 152
- 239000008194 pharmaceutical composition Substances 0.000 claims description 131
- 239000000090 biomarker Substances 0.000 claims description 54
- 206010047642 Vitiligo Diseases 0.000 claims description 22
- 208000004631 alopecia areata Diseases 0.000 claims description 21
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 20
- 206010043207 temporal arteritis Diseases 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 238000002203 pretreatment Methods 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 60
- 239000003814 drug Substances 0.000 description 27
- 201000000306 sarcoidosis Diseases 0.000 description 27
- 206010025135 lupus erythematosus Diseases 0.000 description 16
- 229940124597 therapeutic agent Drugs 0.000 description 16
- 208000005777 Lupus Nephritis Diseases 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 3
- 201000003646 skin sarcoidosis Diseases 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 206010011674 Cutaneous sarcoidosis Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- -1 IFNγ Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960003697 abatacept Drugs 0.000 description 2
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 229960003270 belimumab Drugs 0.000 description 2
- 206010007604 cardiac sarcoidosis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 208000000288 neurosarcoidosis Diseases 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical group NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 206010050551 Lupus-like syndrome Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 238000004148 unit process Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1618961.5 | 2016-11-10 | ||
| GB1618963.1 | 2016-11-10 | ||
| GB201618959 | 2016-11-10 | ||
| GB1618959.9 | 2016-11-10 | ||
| GB201618961 | 2016-11-10 | ||
| GB201618962 | 2016-11-10 | ||
| GB1618964.9 | 2016-11-10 | ||
| GB1618960.7 | 2016-11-10 | ||
| GB201618960 | 2016-11-10 | ||
| GB1618962.3 | 2016-11-10 | ||
| GB201618963 | 2016-11-10 | ||
| GB201618964 | 2016-11-10 | ||
| PCT/EP2017/078701 WO2018087202A1 (en) | 2016-11-10 | 2017-11-09 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534304A JP2019534304A (ja) | 2019-11-28 |
| JP2019534304A5 true JP2019534304A5 (enExample) | 2020-12-17 |
Family
ID=60388032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524273A Withdrawn JP2019534304A (ja) | 2016-11-10 | 2017-11-09 | 炎症性疾患の治療のための化合物及びその医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190314382A1 (enExample) |
| EP (1) | EP3538103A1 (enExample) |
| JP (1) | JP2019534304A (enExample) |
| AU (1) | AU2017358703A1 (enExample) |
| CA (1) | CA3043396A1 (enExample) |
| RU (1) | RU2019117562A (enExample) |
| TW (1) | TW201821080A (enExample) |
| WO (1) | WO2018087202A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019132654A1 (en) * | 2017-12-27 | 2019-07-04 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| WO2020009566A1 (en) * | 2018-07-04 | 2020-01-09 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
| EP3941474A2 (en) | 2019-03-19 | 2022-01-26 | Incyte Corporation | Biomarkers for vitiligo |
| MA56215A (fr) | 2019-06-10 | 2022-04-20 | Incyte Corp | Traitement topique du vitiligo par un inhibiteur de jak |
| JP7518900B2 (ja) * | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CN115282168B (zh) * | 2022-08-30 | 2024-05-31 | 马应龙大健康有限公司 | 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002623A1 (ja) | 2003-07-03 | 2005-01-13 | Japan Science And Technology Agency | サルコイドーシスの治療薬と治療方法 |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| HUE040127T2 (hu) * | 2012-03-29 | 2019-02-28 | Univ Columbia | Eljárások hajhullási rendellenességek kezelésére |
| UY34855A (es) | 2012-06-22 | 2014-01-31 | Galapagos Nv | Aminotriazolopiridina para usar el tratamiento de la inflamación y composiciones farmacéuticas de ella. |
| CA2926361A1 (en) * | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| WO2016165953A1 (en) | 2015-04-13 | 2016-10-20 | Galapagos Nv | Methods for the treatment of inflammatory disorders |
| WO2016165952A1 (en) | 2015-04-13 | 2016-10-20 | Galapagos Nv | Methods for the treatment of cardiovascular disorders |
| AU2016259023A1 (en) * | 2015-05-07 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for promoting hair growth |
-
2017
- 2017-11-09 CA CA3043396A patent/CA3043396A1/en not_active Abandoned
- 2017-11-09 WO PCT/EP2017/078701 patent/WO2018087202A1/en not_active Ceased
- 2017-11-09 US US16/348,799 patent/US20190314382A1/en not_active Abandoned
- 2017-11-09 JP JP2019524273A patent/JP2019534304A/ja not_active Withdrawn
- 2017-11-09 AU AU2017358703A patent/AU2017358703A1/en not_active Abandoned
- 2017-11-09 EP EP17800795.1A patent/EP3538103A1/en not_active Withdrawn
- 2017-11-09 RU RU2019117562A patent/RU2019117562A/ru not_active Application Discontinuation
- 2017-11-10 TW TW106139074A patent/TW201821080A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534304A5 (enExample) | ||
| EP1613296B1 (en) | Methods for treatment of parkinson's disease | |
| JP5819328B2 (ja) | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 | |
| CN116059204A (zh) | 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法 | |
| Tendera et al. | The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina | |
| JP2020526483A5 (enExample) | ||
| EP2838530B1 (en) | Methods for treating parkinson's disease | |
| CN101511366A (zh) | 在心肌显像方法期间用于增加患者耐受性的方法和组合物 | |
| RU2019117562A (ru) | Соединения и их фармацевтические композиции для лечения воспалительных заболеваний | |
| JP2023520469A (ja) | ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法 | |
| AU2020278236A1 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| JP2014520856A (ja) | 併用ａｌｓ療法 | |
| EP3154517A1 (en) | Stabilized oxymetazoline formulations and their uses | |
| CN101677972A (zh) | 一种用于治疗神经变性疾病的奈拉美生的新组合物 | |
| UA112406C2 (uk) | Фармацевтична комбінація, яка містить тестостерон та інгібітор фде5, для лікування жіночої сексуальної дисфункції | |
| US20230147835A1 (en) | Methods of treating systemic sclerosis | |
| KR102728341B1 (ko) | 원형탈모증의 치료 | |
| EP3265095B1 (en) | Use of n-desmethylclobazam in the treatment of chronic pain disorders and related methods | |
| CN107249596A (zh) | 多发性骨髓瘤的帕比司他剂量 | |
| TW201705957A (zh) | 額葉功能障礙之治療劑 | |
| HK40087403A (zh) | 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 | |
| Van Wart et al. | PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF TOLVAPTAN ON FLUID AND ELECTROLYTE BALANCE IN PATIENTS WITH HYPERVOLEMIC HYPONATREMIA | |
| WO2017153850A1 (en) | Perhexiline dosing regimens for use in the treatment of hypertrophic cardiomyopathy | |
| HK1177139A (en) | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |